[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Nanfang Hospital, Southern Medical University\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":610},{"pageToken":4,"total":5,"offset":6,"count":7,"results":8},null,151,0,25,[9,48,74,98,117,137,172,194,214,237,258,282,310,334,353,384,406,433,460,481,506,524,546,567,591],{"id":10,"slug":11,"hasResults":12,"nctId":13,"briefTitle":14,"officialTitle":15,"acronym":4,"eligibilityCriteria":16,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":23,"conditions":24,"keywords":28,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":36,"lastUpdatePostDateStruct":37,"startDateStruct":40,"completionDateStruct":42,"leadSponsor":44,"locationsCount":47},"100652599","pd-l1-inhibitor-rechallenge-after-immunotherapy-related-pneumonitis-in-patients-with-lung-cancer-100652599",false,"NCT07775820","PD-L1 Inhibitor Rechallenge After Immunotherapy-Related Pneumonitis in Patients With Lung Cancer","Efficacy and Safety of PD-L1 Inhibitor Rechallenge After Immune Checkpoint Inhibitor-Related Pneumonitis in Patients With Lung Cancer: A Multicenter Real-World Study","Inclusion Criteria:\n\n1. Age 18 years or older.\n2. Histologically confirmed lung cancer.\n3. Development of checkpoint inhibitor pneumonitis after treatment with immune checkpoint inhibitor.\n4. Eastern Cooperative Oncology Group performance status of 0, 1, or 2.\n5. Provision of written informed consent.\n\nExclusion Criteria:\n\n1. Incomplete clinical information required for the study analyses.\n2. Considered unsuitable for participation by the investigator.","ALL","18 Years",{"count":20,"type":21},150,"ESTIMATED","OBSERVATIONAL","This multicenter observational study will evaluate the safety and effectiveness of immune checkpoint inhibitor rechallenge in adults with lung cancer who developed checkpoint inhibitor pneumonitis.\n\nThe study will use both retrospective medical records and prospective follow-up data. Participants will not be assigned to any treatment by the study protocol. All treatment decisions will be made by the treating physicians as part of routine clinical care.\n\nParticipants will be classified into three groups according to their subsequent treatment: rechallenge with a PD-L1 inhibitor, rechallenge with a PD-1 inhibitor, or no immune checkpoint inhibitor rechallenge. The primary outcome is the recurrence of checkpoint inhibitor pneumonitis after rechallenge. Secondary outcomes include immune-related adverse events, progression-free survival, overall survival, objective response rate, and disease control rate at 24 weeks.\n\nApproximately 150 participants will be included across multiple study centers in China.",[25,26,27],"Lung Cancer","Rechallenge","Checkpoint Inhibitor Pneumonitis",[29,30,31,32,27,33,34],"Immune Checkpoint Inhibitor","PD-L1 Inhibitor","PD-1 Inhibitor","Immune Checkpoint Inhibitor Rechallenge","Immune-Related Adverse Events","Real-World Study","RECRUITING","2026-08-18",{"date":38,"type":39},"2026-08-20","ACTUAL",{"date":41,"type":39},"2025-10-20",{"date":43,"type":21},"2027-06-30",{"name":45,"class":46},"Nanfang Hospital, Southern Medical University","OTHER",5,{"id":49,"slug":50,"hasResults":12,"nctId":51,"briefTitle":52,"officialTitle":53,"acronym":4,"eligibilityCriteria":54,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":55,"enrollmentInfo":56,"targetDuration":4,"studyType":58,"phases":59,"briefSummary":61,"conditions":62,"keywords":4,"overallStatus":65,"whyStopped":4,"lastUpdateSubmitDate":66,"lastUpdatePostDateStruct":67,"startDateStruct":69,"completionDateStruct":71,"leadSponsor":73,"locationsCount":4},"100651598","cold-versus-hot-snare-endoscopic-mucosal-resection-for-intermediate-size-flat-nonpedunculated-colorectal-polyps-100651598","NCT07764224","Cold Versus Hot Snare Endoscopic Mucosal Resection for Intermediate-Size Flat Nonpedunculated Colorectal Polyps","Cold Versus Hot Snare Endoscopic Mucosal Resection for Intermediate-Size Flat Nonpedunculated Colorectal Polyps: A Multicenter, Prospective, Randomized, Non-Inferiority Clinical Trial","Inclusion Criteria:\n\n1. Subjects aged 18-75 years, irrespective of gender;\n2. Flat sessile colorectal polyps confirmed by colonoscopy, classified as Paris classification 0-Is or 0-IIa, with a measured diameter ranging from 10 to 20 mm;\n3. Subjects voluntarily agree to receive endoscopic treatment and sign written informed consent.\n\nExclusion Criteria:\n\n1. Colonoscopic findings suggestive of submucosal invasion or malignant transformation of colorectal polyps;\n2. Previous history of colorectal surgery;\n3. Previous history of inflammatory bowel disease, familial adenomatous polyposis, or colorectal cancer;\n4. Failure to discontinue anticoagulant and antiplatelet medications for a minimum of 1 week prior to the procedure;\n5. Known coagulation disorders or bleeding diathesis;\n6. Pregnant or breastfeeding women;\n7. Patients complicated with malignant tumors, severe cardiovascular and cerebrovascular diseases, liver cirrhosis, chronic kidney disease, or other severe comorbidities that preclude tolerance to endoscopic resection.","75 Years",{"count":57,"type":21},968,"INTERVENTIONAL",[60],"NA","This multicenter, prospective, randomized, non-inferiority trial aimed to compare the efficacy and safety of cold snare endoscopic mucosal resection (CS-EMR) and hot snare endoscopic mucosal resection (HS-EMR) for resection of intermediate-size (10-20 mm) flat nonpedunculated colorectal polyps.",[63,64],"Colorectal Polyps","Endoscopic Mucosal Resection","NOT_YET_RECRUITING","2026-08-10",{"date":68,"type":39},"2026-08-13",{"date":70,"type":21},"2026-08",{"date":72,"type":21},"2029-02",{"name":45,"class":46},{"id":75,"slug":76,"hasResults":12,"nctId":77,"briefTitle":78,"officialTitle":78,"acronym":4,"eligibilityCriteria":79,"healthyVolunteers":12,"sex":17,"minAge":80,"maxAge":81,"enrollmentInfo":82,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":84,"conditions":85,"keywords":87,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":90,"lastUpdatePostDateStruct":91,"startDateStruct":92,"completionDateStruct":94,"leadSponsor":96,"locationsCount":97},"100651628","dynamic-functional-imaging-phenotyping-and-disease-progression-risk-assessment-in-copd-using-dynamic-chest-radiography-a-multicenter-retrospective-study-100651628","NCT07762573","Dynamic Functional Imaging Phenotyping and Disease Progression Risk Assessment in COPD Using Dynamic Chest Radiography: A Multicenter Retrospective Study","Inclusion Criteria:\n\n1. Aged 30-85 years.\n2. Male or female.\n3. Patients who underwent pulmonary function testing and dynamic chest radiography at the hospital.\n\nExclusion Criteria:\n\n1. Incomplete medical records.\n2. Considered unsuitable for inclusion in the study at the investigator's discretion.","30 Years","85 Years",{"count":83,"type":21},2500,"To evaluate the utility of DCR-derived parameters for identifying dynamic functional imaging phenotypes, assessing disease severity, and predicting the risk of disease progression in COPD.",[86],"Chronic Obstructive Pulmonary Disease",[88,89],"Chronic obstructive pulmonary disease","Dynamic Chest Radiography","2026-08-09",{"date":68,"type":39},{"date":93,"type":39},"2026-08-03",{"date":95,"type":21},"2030-01-30",{"name":45,"class":46},1,{"id":99,"slug":100,"hasResults":12,"nctId":101,"briefTitle":102,"officialTitle":103,"acronym":4,"eligibilityCriteria":104,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":105,"enrollmentInfo":106,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":108,"conditions":109,"keywords":4,"overallStatus":65,"whyStopped":4,"lastUpdateSubmitDate":90,"lastUpdatePostDateStruct":112,"startDateStruct":113,"completionDateStruct":114,"leadSponsor":116,"locationsCount":97},"100651542","mngs-for-ifd-in-patients-with-hematological-malignancies-100651542","NCT07763184","mNGS for IFD in Patients With Hematological Malignancies","Application of Peripheral Blood Pathogen Metagenomic Next-Generation Sequencing in the Diagnosis of Invasive Fungal Disease in Patients With Hematological Malignancies","Inclusion Criteria:\n\n* Voluntarily signed the Informed Consent Form (ICF);\n* Diagnosed with a hematological malignancy and receiving necessary treatment according to clinical medical orders;\n* Presenting with clinical symptoms, signs, or imaging features suspected of IFD. Clinical symptoms or signs include fever, cough, expectoration, chest pain, skin and soft tissue infectious lesions, or symptoms related to other deep tissue involvement. Imaging features vary depending on the site of infection, including: if involving the lower respiratory tract\u002Flungs, a CT scan showing at least the presence of dense, well-defined lesions (with or without a halo sign), air crescent sign, cavity, wedge-shaped\u002Fsegmental or lobar consolidations, reversed halo sign, etc.; if involving the central nervous system (CNS), an MRI\u002FCT scan indicating meningeal enhancement; or corresponding imaging features for the involvement of other deep tissues.\n\nExclusion Criteria:\n\n* Unable to undergo necessary conventional microbiological testing or imaging examinations;\n* Deemed unsuitable to participate in this study by the investigator.","65 Years",{"count":107,"type":21},50,"Invasive fungal disease (IFD) refers to an infectious disease caused by fungi invading the human body, growing and reproducing in tissues, organs, or blood, and leading to inflammatory responses and tissue damage. Due to the suppression of immune system function during the disease and its treatment process, patients with hematological malignancies are prone to opportunistic infections, including IFD, with the lungs being the most common site of infection. In patients with hematological malignancies, IFD is often difficult to diagnose and progresses rapidly. Some patients become critically ill, which severely affects their prognosis. With the rapid development of molecular biology techniques, metagenomic next-generation sequencing (mNGS) of pathogenic microorganisms-as a broad-coverage, highly sensitive diagnostic tool with a short reporting cycle-has been widely applied in the etiological diagnosis of clinical infectious diseases. However, its clinical value in the diagnosis of IFD remains to be explored. This study is a single-center, single-arm, open-label clinical study to to explore the clinical performance of peripheral blood mNGS in the diagnosis and treatment of IFD in patients with hematological malignancies.",[110,111],"Hematological Malignancies","Invasive Fungal Disease",{"date":68,"type":39},{"date":66,"type":21},{"date":115,"type":21},"2027-12-31",{"name":45,"class":46},{"id":118,"slug":119,"hasResults":12,"nctId":120,"briefTitle":121,"officialTitle":122,"acronym":4,"eligibilityCriteria":123,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":55,"enrollmentInfo":124,"targetDuration":4,"studyType":58,"phases":126,"briefSummary":127,"conditions":128,"keywords":4,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":90,"lastUpdatePostDateStruct":130,"startDateStruct":132,"completionDateStruct":134,"leadSponsor":136,"locationsCount":97},"100651374","underwater-endoscopic-mucosal-resection-versus-endoscopic-submucosal-dissection-for-the-treatment-of-small-rectal-neuroendocrine-tumors-100651374","NCT07759960","Underwater Endoscopic Mucosal Resection Versus Endoscopic Submucosal Dissection for the Treatment of Small Rectal Neuroendocrine Tumors","Underwater Endoscopic Mucosal Resection Versus Endoscopic Submucosal Dissection for the Treatment of Small Rectal Neuroendocrine Tumors: A Prospective, Multicenter, Non-inferiority Trial","Inclusion Criteria:\n\n1. Age from 18 to 75 years;\n2. With a high suspicion or evidence of rectal NET assessed using EUS, CT scan or colonoscopy;\n3. With tumor size ≤10 mm assessed by colonoscopy or EUS;\n4. Plan to receive UEMR or ESD treatment and provide written informed consent.\n\nExclusion Criteria:\n\n1. Unable to tolerate ESD or UEMR as assessed by the research team;\n2. Complicated with serious diseases such as malignant tumor, which may lead to shorter life expectancy, the research team considers that it is not suitable for inclusion in the study after comprehensive evaluation;\n3. Rectal NET with lymph node metastasis or distant metastasis;\n4. Received resection of rectal neuroendocrine tumor by other surgical procedures;\n5. Multiple rectal neuroendocrine tumors;\n6. Vulnerable groups such as pregnant women or patients with mental disorders;\n7. Poor compliance, unable to cooperate with treatment.",{"count":125,"type":21},174,[60],"Underwater endoscopic mucosal resection (UEMR) and endoscopic submucosal dissection (ESD) have both been reported to be two effective treatment methods for small rectal neuroendocrine tumor (NET). However, there is no consensus on the best method for the endoscopic resection of rectal NET. Therefore, we aimed to compare the efficacy and safety of UEMR and ESD for the treatment of small rectal NET.",[129],"Rectal Neuroendocrine Tumor",{"date":131,"type":39},"2026-08-12",{"date":133,"type":39},"2026-04-14",{"date":135,"type":21},"2029-12",{"name":45,"class":46},{"id":138,"slug":139,"hasResults":12,"nctId":140,"briefTitle":141,"officialTitle":142,"acronym":143,"eligibilityCriteria":144,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":55,"enrollmentInfo":145,"targetDuration":147,"studyType":22,"phases":4,"briefSummary":148,"conditions":149,"keywords":153,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":164,"lastUpdatePostDateStruct":165,"startDateStruct":166,"completionDateStruct":168,"leadSponsor":170,"locationsCount":171},"100651102","early-complications-after-flow-diverter-versus-stent-assisted-coiling-for-unruptured-wide-neck-intracranial-bifurcation-aneurysms-100651102","NCT07754188","Early Complications After Flow Diverter Versus Stent-Assisted Coiling for Unruptured Wide-Neck Intracranial Bifurcation Aneurysms","Early Complications After Flow Diverter Versus Stent-Assisted Coiling for Unruptured Wide-Neck Intracranial Bifurcation Aneurysms: A Prospective Real-World Cohort Study","FD-SAC BAS","Inclusion Criteria:\n\n* Voluntarily provides written informed consent.\n* Aged 18 to 75 years.\n* Diagnosed by CTA, MRA, or DSA as having an unruptured, bifurcation, saccular, wide-neck intracranial aneurysm.\n* Able to understand the purpose of the study.\n\nExclusion Criteria:\n\n* Patients with two or more multiple aneurysms, all of which require treatment within 1 year.\n* Patients with other cerebrovascular diseases such as arteriovenous malformation or moyamoya disease.\n* Patients with ruptured aneurysms or narrow-neck aneurysms.\n* Patients who experienced stroke, including cerebral hemorrhage or cerebral infarction, within the past 1 month.\n* Patients with poor clinical condition, defined as modified Rankin Scale score ≥3.\n* Patients who have already planned to undergo surgical or interventional treatment within 3 months.\n* Patients considered by the investigator to be unsuitable for endovascular treatment, such as those with no suitable vascular access, excessively tortuous vessels, or difficulty in stent delivery.\n* Patients unsuitable for anesthesia or endovascular treatment, including those with major heart, lung, liver, spleen, or kidney disease, brain tumor, severe active infection, disseminated intravascular coagulation, or a history of severe psychiatric disorder.\n* Patients unable to receive antiplatelet or anticoagulant therapy.\n* Patients with a previous or possible severe reaction to contrast agents that would prevent completion of pre-treatment medication or treatment.\n* Patients with a known history of allergy to cobalt-chromium or nickel-titanium alloy materials.\n* Patients who participated in another drug or medical device clinical trial before enrollment and have not reached the time point of the primary endpoint.\n* Pregnant or lactating women.\n* Patients with life expectancy less than 12 months.\n* Patients judged by the investigator to have poor compliance and inability to complete the study as required",{"count":146,"type":21},274,"30 Days","This prospective real-world cohort study aims to compare early postoperative complications between flow diverter treatment and stent-assisted coiling in patients with unruptured wide-neck intracranial bifurcation aneurysms. A total of 274 patients from three centers in China will be enrolled and assigned to the flow diverter group or the stent-assisted coiling group according to the treatment received in routine clinical practice. The primary outcome is a composite of any stroke or all-cause death within 30 days after the procedure. The study will also collect demographic, clinical, laboratory, imaging, aneurysm morphological, procedural, and follow-up data to evaluate the safety of these two endovascular treatment strategies in a real-world setting.",[150,151,152],"Unruptured Intracranial Aneurysm","Intracranial Bifurcation Aneurysm","Wide-Neck Aneurysm",[154,155,156,157,158,159,160,161,162,163],"Intracranial bifurcation aneurysm","Wide-neck aneurysm","Flow diverter","Stent-assisted coiling","Endovascular treatment","Early complications","Stroke","All-cause mortality","Real-world study","Prospective cohort","2026-08-04",{"date":66,"type":39},{"date":167,"type":39},"2026-03-19",{"date":169,"type":21},"2028-03-19",{"name":45,"class":46},3,{"id":173,"slug":174,"hasResults":12,"nctId":175,"briefTitle":176,"officialTitle":177,"acronym":4,"eligibilityCriteria":178,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":55,"enrollmentInfo":179,"targetDuration":4,"studyType":58,"phases":181,"briefSummary":182,"conditions":183,"keywords":4,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":187,"lastUpdatePostDateStruct":188,"startDateStruct":189,"completionDateStruct":191,"leadSponsor":192,"locationsCount":193},"100650314","modified-single-incision-plus-one-port-versus-conventional-five-port-laparoscopic-pancreaticoduodenectomy-for-nonpancreatic-periampullary-adenocarcinomas-100650314","NCT07744087","Modified Single-Incision Plus One-Port Versus Conventional Five-Port Laparoscopic Pancreaticoduodenectomy for Nonpancreatic Periampullary Adenocarcinomas","Modified \"Single-Incision Plus One \"Versus Conventional \"Five-Port\" Laparoscopic Pancreaticoduodenectomy for Nonpancreatic Periampullary Adenocarcinomas: Study Protocol for A Multicentre Randomised Controlled Trial","Inclusion Criteria:\n\n* Age 18 years or older and younger than 75 years.\n* Histopathologically confirmed non-pancreatic periampullary carcinoma, or a high clinical suspicion of non-pancreatic periampullary carcinoma when preoperative pathological confirmation is unavailable.\n* Determined by preoperative multidisciplinary team evaluation to require pancreaticoduodenectomy.\n* Able to understand and comply with study procedures.\n* Able and willing to provide written informed consent before any study-specific screening procedure.\n* Expected to benefit from therapeutic pancreaticoduodenectomy according to applicable clinical guidelines.\n\nExclusion Criteria:\n\n* Distant metastasis, including peritoneal, hepatic, distant lymph node, or other organ metastasis.\n* Requirement for distal, central, or total pancreatectomy, or another palliative procedure.\n* Preoperative American Society of Anesthesiologists physical status classification of 4 or higher.\n* Concurrent malignancy other than the target cancer.\n* Pregnancy or breastfeeding.\n* Severe psychiatric disorder that would interfere with study participation.\n* Receipt of neoadjuvant chemotherapy or radiotherapy before surgery.\n* Vascular invasion requiring vascular resection, as determined by the multidisciplinary team based on preoperative abdominal imaging.\n* Body mass index greater than 35 kg\u002Fm².\n* Participation in another clinical trial within the previous 3 months.",{"count":180,"type":21},232,[60],"This multicenter, randomized, controlled, non-inferiority trial will compare modified single-incision plus one-port laparoscopic pancreaticoduodenectomy (mSILPD+1) with conventional five-port laparoscopic pancreaticoduodenectomy (CLPD) in adults with histologically confirmed or highly suspected non-pancreatic periampullary carcinoma who are candidates for pancreaticoduodenectomy. A total of 232 participants will be randomly assigned in a 1:1 ratio. Outcome assessors who adjudicate complications and interpret imaging will be masked to treatment assignment. The primary outcomes are all-cause mortality within 90 days after surgery and overall survival at 1 year after surgery. Secondary outcomes will assess postoperative complications, surgical performance, postoperative recovery, disease-free survival, quality of life, and health-care costs.",[184,185,186],"Ampullary Carcinoma","Duodenal Adenocarcinoma","Distal Cholangiocarcinoma","2026-08-02",{"date":164,"type":39},{"date":190,"type":39},"2026-06-04",{"date":135,"type":21},{"name":45,"class":46},4,{"id":195,"slug":196,"hasResults":12,"nctId":197,"briefTitle":198,"officialTitle":199,"acronym":4,"eligibilityCriteria":200,"healthyVolunteers":201,"sex":17,"minAge":202,"maxAge":4,"enrollmentInfo":203,"targetDuration":4,"studyType":58,"phases":205,"briefSummary":206,"conditions":207,"keywords":4,"overallStatus":65,"whyStopped":4,"lastUpdateSubmitDate":209,"lastUpdatePostDateStruct":210,"startDateStruct":211,"completionDateStruct":212,"leadSponsor":213,"locationsCount":4},"100650303","impact-of-linked-color-imaging-on-sessile-serrated-lesion-miss-rate-100650303","NCT07745842","Impact of Linked Color Imaging on Sessile Serrated Lesion Miss Rate","Impact of Linked Color Imaging on Sessile Serrated Lesion Miss Rate: a Multicenter Tandem Rondomized Controlled Trial","Inclusion Criteria:\n\n1. Subjects aged ≥45 years, regardless of gender;\n2. Subjects undergoing screening colonoscopy;\n3. Subjects with no prior colonoscopy;\n4. Voluntarily provide written informed consent.\n\nExclusion Criteria:\n\n1. Subjects unable to cooperate with or tolerate colonoscopy;\n2. Subjects with inflammatory bowel disease;\n3. Known or highly suspected colorectal obstruction;\n4. History of colorectal surgery;\n5. Chronic recurrent constipation;\n6. Failure to discontinue anticoagulants or antiplatelet agents for at least 1 week before the procedure;\n7. Poor bowel preparation with an inadequate Aronchick scale score during colonoscopy;\n8. Failed cecal intubation;\n9. High-risk conditions including severe cardiovascular and cerebrovascular diseases, uncorrected severe anemia or active infection;\n10. Pregnant or breastfeeding women;\n11. Subjects deemed ineligible for participation in this trial at the investigator's discretion.",true,"45 Years",{"count":204,"type":21},2072,[60],"This prospective, multicenter randomized controlled trial aimed to investigate whether linked color imaging (LCI) could reduce the miss rate of sessile serrated lesions (SSLs) during tandem colonoscopy compared with conventional white-light imaging (WLI).",[208],"Colorectal Sessile Serrated Lesion","2026-07-30",{"date":164,"type":39},{"date":70,"type":21},{"date":72,"type":21},{"name":45,"class":46},{"id":215,"slug":216,"hasResults":12,"nctId":217,"briefTitle":218,"officialTitle":219,"acronym":220,"eligibilityCriteria":221,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":222,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":224,"conditions":225,"keywords":228,"overallStatus":65,"whyStopped":4,"lastUpdateSubmitDate":209,"lastUpdatePostDateStruct":232,"startDateStruct":233,"completionDateStruct":234,"leadSponsor":236,"locationsCount":97},"100649981","impact-of-perioperative-antibiotic-use-on-surgical-scarring-100649981","NCT07741591","Impact of Perioperative Antibiotic Use on Surgical Scarring","Perioperative Antibiotic Use and Its Impact on Postoperative Scarring: A Retrospective Study","PASS","Inclusion Criteria:\n\n* Age 18 years or older.\n* Underwent body surface surgery at Nanfang Hospital between January 1, 2005 and January 1, 2025, with a linear surgical incision scar.\n* Presented to the Department of Plastic Surgery at Nanfang Hospital for surgical scar-related care.\n* Had no medical encounter record at Nanfang Hospital from January 1, 2025 to the time of study screening.\n* Available clear surgical records and perioperative medication records.\n\nExclusion Criteria:\n\n* Known tendency for pathological scarring or scar constitution.\n* History of chronic skin disease in the surgical area, such as psoriasis or eczema.\n* Uncontrolled diabetes mellitus, malnutrition, hypoalbuminemia, or long-term use of immunosuppressive agents or glucocorticoids.\n* Target scar received any scar-specific treatment after surgery, such as laser therapy, radiotherapy, drug injection, or surgical revision.",{"count":223,"type":21},5000,"This retrospective observational cohort study will evaluate whether perioperative antibiotic use is associated with long-term surgical scar outcomes. The study will include adult patients who underwent body surface surgery at Nanfang Hospital between January 1, 2005 and January 1, 2025 and have available surgical, medication, and scar-related clinical records.\n\nThe study will not assign participants to any treatment. Researchers will review existing medical records, perioperative antibiotic exposure, surgical characteristics, complications, and scar assessments or photographs. Scar outcomes will be assessed using modified visual analogue scale scores, scar width, scar type, and scar-related complications.",[226,227],"Surgical Scar","Postoperative Scar",[229,226,227,230,231],"Perioperative Antibiotics","Scar Assessment","Visual Analogue Scale",{"date":93,"type":39},{"date":93,"type":21},{"date":235,"type":21},"2026-08-15",{"name":45,"class":46},{"id":238,"slug":239,"hasResults":12,"nctId":240,"briefTitle":241,"officialTitle":242,"acronym":4,"eligibilityCriteria":243,"healthyVolunteers":12,"sex":17,"minAge":4,"maxAge":18,"enrollmentInfo":244,"targetDuration":4,"studyType":58,"phases":246,"briefSummary":247,"conditions":248,"keywords":4,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":250,"lastUpdatePostDateStruct":251,"startDateStruct":253,"completionDateStruct":255,"leadSponsor":257,"locationsCount":97},"100645789","prevention-of-epstein-barr-virus-reactivation-with-the-atg-based-haploidentical-protocol-combined-with-rituximab-in-children-undergoing-allogeneic-hematopoietic-stem-cell-transplantation-100645789","NCT07693881","Prevention of Epstein-Barr Virus Reactivation With the ATG-based Haploidentical Protocol Combined With Rituximab in Children Undergoing Allogeneic Hematopoietic Stem Cell Transplantation","Prevention of Epstein-Barr Virus Reactivation With the ATG-based Haploidentical Protocol Combined With Rituximab in Children Undergoing Allogeneic Hematopoietic Stem Cell Transplantation: A Prospective, Multicenter, Open-Label, Randomized Controlled Clinical Trial","Inclusion Criteria:\n\n* ECOG performance status score of 0-1, or Karnofsky Performance Status (KPS) score \\> 80.\n* Diagnosis of a disease that has an indication for allogeneic hematopoietic stem cell transplantation.\n* Donor source is a related HLA haploidentical (half-matched) family donor.\n* Use of an \"ATG-based\" transplantation conditioning\u002Fprotocol.\n* Written informed consent obtained from the patient's legal guardian prior to enrollment in this study.\n\nExclusion Criteria:\n\n* Lansky performance score \\\u003C 60.\n* Diagnosis of EBV-associated hemophagocytic lymphohistiocytosis (HLH) or chronic active EBV infection.\n* Serum EBV DNA level \\> 100 U\u002FmL before transplantation.\n* Use of B-cell depleting immunotherapy (e.g., rituximab, blinatumomab, etc.) within 2 weeks prior to preconditioning.\n* Known allergy or hypersensitivity to rituximab.\n* Severe organ dysfunction\n* The subject or their legal guardian is unwilling or unable to comply with the protocol, or refuses to sign the informed consent document.\n* Patients deemed by the investigator to be unsuitable for participation in this trial.",{"count":245,"type":21},106,[60],"The goal of this clinical trial is to learn if adding rituximab to the ATG-based Protocol can prevent Epstein-Barr virus (EBV) from reactivating in children who have received an allogeneic haploidentical hematopoietic stem cell transplant. It will also learn about the safety of adding rituximab. The main questions it aims to answer are:\n\nDoes giving rituximab twice during the conditioning regimen lower the number of children who have EBV reactivation after transplant?\n\nWhat medical problems or side effects do children experience when they receive rituximab in addition to the ATG-based Protocol?\n\nResearchers will compare the group that receives rituximab (two doses before transplant) with a control group that receives no rituximab, to see if the addition of rituximab effectively prevents EBV reactivation.\n\nParticipants will:\n\nReceive either rituximab (two doses during the preconditioning phase) or no extra treatment (control group), depending on which group they are assigned to\n\nHave regular follow-up visits for blood tests to monitor their EBV-DNA levels\n\nKeep a record of any symptoms or health changes they notice between visits",[249],"EBV Infection After Allogenic HSCT","2026-07-21",{"date":252,"type":39},"2026-07-23",{"date":254,"type":21},"2026-07-01",{"date":256,"type":21},"2029-12-31",{"name":45,"class":46},{"id":259,"slug":260,"hasResults":12,"nctId":261,"briefTitle":262,"officialTitle":262,"acronym":4,"eligibilityCriteria":263,"healthyVolunteers":201,"sex":17,"minAge":264,"maxAge":265,"enrollmentInfo":266,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":267,"conditions":268,"keywords":270,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":274,"lastUpdatePostDateStruct":275,"startDateStruct":277,"completionDateStruct":279,"leadSponsor":281,"locationsCount":97},"100566302","exploring-the-diagnostic-performance-of-dynamic-chest-radiology-in-chronic-obstructive-pulmonary-disease-100566302","NCT06653413","Exploring the Diagnostic Performance of Dynamic Chest Radiology in Chronic Obstructive Pulmonary Disease","Inclusion Criteria:\n\n\\- COPD group: (1) Patients ≥30 years of age and ≤ 80 years of age who meet the 2023 GOLD Guidelines for the Diagnosis and Treatment of Chronic Obstructive Pulmonary Disease, i.e., anyone who complains of dyspnea, chronic cough or sputum, a history of recurrent lower respiratory infection and\u002For exposure to disease risk factors, Moreover, pulmonary function examination indicated that FEV1\u002FFVC \\\u003C0.7 after bronchodilator was used to confirm COPD. FEV1%pred is used to determine the severity of airflow obstruction: Grade GOLD 1 (mild) : FEV1%pred ≥ 80%, Grade GOLD2 (moderate) : 50% ≤ FEV1%pred \\\u003C 80%, grade GOLD3 (severe) : 30% ≤ FEV1%pred \\\u003C 50%, GOLD4 grade (extremely severe) : FEV1%pred \\\u003C 30%; (2) Signing informed consent; (3) Can cooperate with the completion of dynamic chest X-ray (complete dynamic chest X-ray positioning for 20 seconds, during which calm breathing, hard breathing, can hold breath for at least 7 seconds).\n\nNormal Group: (1) Age ≥30 years old and ≤ 80 years old; (2) Normal pulmonary ventilation function; (3) Exclude chronic airway diseases (such as COPD, asthma, bronchiectasis, etc.); (4) Signing informed consent; (5) Can cooperate with the completion of dynamic chest X-ray (complete dynamic chest X-ray positioning for 20 seconds, during which calm breathing, hard breathing, can hold breath for at least 7 seconds).\n\nExclusion Criteria:\n\n* COPD group: (1) A history of cancer, lung surgery, other lung diseases (such as pneumonia, active tuberculosis, severe bronchiectasis); (2) Combined with muscle-related diseases such as myasthenia gravis or wasting diseases that affect muscle mass such as severe hyperthyroidism and advanced malignant diseases; (3) Pregnant or lactating women; (4) Significant radiation exposure (dose \\>10mSv) was involved in the 12 months prior to study participation. Normal Group: (1) Have acute or chronic cardiopulmonary disease in the past, abnormal lung physical examination and lung imaging examination in the past, and have a history of infectious diseases within the past 1 month; (2) Pregnant or lactating women; (3) Significant radiation exposure (dose \\>10mSv) was involved in the 12 months prior to study participation.","40 Years","80 Years",{"count":83,"type":21},"The prevalence of chronic obstructive pulmonary disease (COPD) is on the rise, leading to an increasing economic and social burden. Currently, the diagnosis and staging of COPD heavily rely on pulmonary function testing. However, limitations such as patient cooperation and comorbidities can hinder accurate diagnosis. In situations like a respiratory pandemic, pulmonary function testing may not be feasible. Dynamic chest radiography has emerged as a promising area of research due to its quick procedure, high patient cooperation, low risk, minimal radiation exposure, and reduced direct contact. Recent clinical studies have started to explore the relationship between dynamic chest X-ray measurements and lung function parameters. However, there is a noticeable scarcity of research focusing on the use of dynamic chest X-ray in aiding the diagnosis of COPD, particularly in Chinese populations where cohort data is lacking. Consequently, there is a pressing need to investigate the correlation between various dynamic chest radiograph parameters and lung function indicators, as well as their potential diagnostic value in COPD.",[269],"Chronic Obstructive Pulmonary Disease (COPD)",[88,271,272,273],"Dynamic chest radiology","Pulmonary function test","Diagnosis","2026-07-17",{"date":276,"type":39},"2026-07-20",{"date":278,"type":39},"2024-01-01",{"date":280,"type":21},"2027-12-30",{"name":45,"class":46},{"id":283,"slug":284,"hasResults":12,"nctId":285,"briefTitle":286,"officialTitle":287,"acronym":288,"eligibilityCriteria":289,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":55,"enrollmentInfo":290,"targetDuration":4,"studyType":58,"phases":292,"briefSummary":293,"conditions":294,"keywords":296,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":302,"lastUpdatePostDateStruct":303,"startDateStruct":305,"completionDateStruct":307,"leadSponsor":309,"locationsCount":97},"100647326","flow-diverter-versus-conventional-endovascular-treatment-for-unruptured-wide-neck-bifurcation-aneurysms-fd-bwa-trial-100647326","NCT07707076","Flow Diverter Versus Conventional Endovascular Treatment for Unruptured Wide-Neck Bifurcation Aneurysms (FD-BWA Trial)","Traditional Approach Versus Flow Diverter for Unruptured Intracranial Wide-neck Bifurcation Aneurysms: a Prospective International Multicenter Randomized Controlled Study (FD-BWA Study)","FD-BWA","Inclusion Criteria:\n\n1. Age 18-75 years;\n2. Diagnosis of unruptured intracranial, bifurcation, saccular, wide-neck aneurysm by DSA\u002FCTA\u002FMRA;\n3. Patients who can understand the purpose of the trial, voluntarily participate and sign the informed consent form.\n\nExclusion Criteria:\n\n1. Patients with two or more multiple aneurysms that all require treatment within 1 year;\n2. Concomitant cerebrovascular diseases such as arteriovenous malformation, moyamoya disease;\n3. Ruptured aneurysms and narrow-neck aneurysms;\n4. Patients who have had a stroke (cerebral hemorrhage, cerebral infarction) within the past 1 month;\n5. Extremely poor clinical condition, modified Rankin Score ≥3;\n6. Patients already scheduled for surgery\u002Finterventional procedure within 3 months;\n7. Patients deemed unsuitable for interventional treatment by the investigator (e.g., no suitable vascular access, excessively tortuous vessels, difficulty delivering stent);\n8. Patients unsuitable for anesthesia or endovascular surgery, such as major diseases of heart, lung, liver, spleen, kidney, brain tumors, severe active infections, disseminated intravascular coagulation, severe mental illness;\n9. Patients unable to receive antiplatelet or anticoagulant therapy;\n10. Patients who have had or may have severe reactions to contrast media precluding pre-treatment medication;\n11. Patients with a definite history of allergy to cobalt-chromium, nickel-titanium alloy materials;\n12. Participation in other drug or medical device clinical trials before enrollment without reaching the primary endpoint timeframe;\n13. Pregnant or breastfeeding women;\n14. Patient's life expectancy less than 12 months;\n15. Investigator judges that the patient has poor compliance and cannot complete the study as required.",{"count":291,"type":21},266,[60],"Brief Summary：\n\nThe goal of this clinical trial is to compare whether the traditional approach (stent-assisted coiling) is associated with a lower complication rate than flow diverter (Pipeline™) treatment for unruptured intracranial wide-neck bifurcation aneurysms. It will also evaluate the long-term imaging outcomes and safety of both treatments. The main questions it aims to answer are:\n\n* Does the traditional approach result in a lower rate of any stroke or all-cause death within one year after treatment compared to the flow diverter?\n* What medical problems do participants experience during and after each treatment?\n* What are the imaging cure and stability rates at 1, 2, and 5 years after treatment?\n\nResearchers will compare the traditional approach (stent-assisted coiling) with the flow diverter (Pipeline™) to determine which treatment has better safety and efficacy outcomes.\n\nParticipants will:\n\n* Be randomly assigned to receive either the flow diverter or traditional stent-assisted coiling\n* Undergo the assigned endovascular procedure\n* Return for follow-up visits at 30 days, 6 months, 1 year, 2 years, and 5 years after surgery for clinical assessments and imaging examinations (DSA, MRA, or CTA)",[295],"Unruptured Intracranial Wide-neck Bifurcation Aneurysms",[297,298,299,300,301],"intracranial aneurysms","wide-neck","bifurcation","flow diverter","unruptured","2026-07-10",{"date":304,"type":39},"2026-07-16",{"date":306,"type":39},"2026-02-10",{"date":308,"type":21},"2030-06-30",{"name":45,"class":46},{"id":311,"slug":312,"hasResults":12,"nctId":313,"briefTitle":314,"officialTitle":314,"acronym":4,"eligibilityCriteria":315,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":265,"enrollmentInfo":316,"targetDuration":4,"studyType":58,"phases":318,"briefSummary":319,"conditions":320,"keywords":322,"overallStatus":65,"whyStopped":4,"lastUpdateSubmitDate":326,"lastUpdatePostDateStruct":327,"startDateStruct":329,"completionDateStruct":331,"leadSponsor":333,"locationsCount":4},"100646442","clinical-efficacy-and-mechanism-research-of-getong-tongluo-capsule-in-ischemic-stroke-100646442","NCT07690020","Clinical Efficacy and Mechanism Research of Getong Tongluo Capsule in Ischemic Stroke","Inclusion Criteria:\n\n1. Voluntarily sign the informed consent form\n2. Aged between 18 and 80 years old\n3. Conform to the diagnosis of acute ischemic stroke referring to the Chinese Guidelines for the Diagnosis and Treatment of Acute Ischemic Stroke (2023)\n4. Hospital admission within 21 days after disease onset\n\nExclusion Criteria:\n\n1. Patients with mild or no neurological deficits on admission: those with a score of 0 on the Modified Rankin Scale (mRS) at admission (defined as completely asymptomatic).\n2. Patients with severe baseline disability: those with a pre-stroke mRS score ≥ 3 (indicating moderate to severe disability requiring partial or full assistance with activities of daily living).\n3. Patients with transient ischemic attack, concomitant cerebral hemorrhage or subarachnoid hemorrhage; those complicated with brain tumor, Alzheimer's disease, psychiatric disorders, or suspected pre-stroke cognitive dysfunction.\n4. Patients complicated with severe cardiac diseases including valvular heart disease, infective endocarditis, myocardial infarction and heart failure; severe hepatic or renal insufficiency, respiratory failure, malignant tumors, or massive gastrointestinal hemorrhage.\n5. Patients who received any preparations containing the same active ingredients as the study drug (e.g., Pueraria lobata) within 2 weeks prior to stroke onset.\n6. Patients with a history of allergy to the study drug or preparations with identical active ingredients.\n7. Patients who received antibiotics within 1 month before onset; those taking probiotics or prebiotics long-term; patients with a past or in-hospital confirmed gastrointestinal disease history.\n8. Pregnant and lactating women.\n9. Patients deemed unsuitable for participation in this trial at the investigator's discretion.",{"count":317,"type":21},216,[60],"The purpose of this single-center, randomized, double-blind, controlled trial is to clarify the clinical efficacy and safety of Getong Tongluo Capsule in patients with ischemic stroke. Combined with gut microbiome and metabolomics techniques, investigators will explore whether this medicine exerts neuroprotective effects via the gut-brain axis. Investigators will further verify its pharmacological mechanism through animal experiments to provide evidence for its clinical application.",[321],"Ischemic Stroke, Acute",[323,324,325],"Post-acute Ischemic Stroke","Ischemic Stroke","Acute Ischemic Stroke","2026-07-07",{"date":328,"type":39},"2026-07-08",{"date":330,"type":21},"2026-08-01",{"date":332,"type":21},"2030-01-31",{"name":45,"class":46},{"id":335,"slug":336,"hasResults":12,"nctId":337,"briefTitle":338,"officialTitle":339,"acronym":4,"eligibilityCriteria":340,"healthyVolunteers":12,"sex":17,"minAge":264,"maxAge":81,"enrollmentInfo":341,"targetDuration":4,"studyType":58,"phases":342,"briefSummary":343,"conditions":344,"keywords":4,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":326,"lastUpdatePostDateStruct":346,"startDateStruct":348,"completionDateStruct":350,"leadSponsor":352,"locationsCount":47},"100645685","pei-gt-trial-for-initial-treatment-of-primary-open-angle-glaucoma-with-cataract-100645685","NCT07700498","PEI-GT Trial for Initial Treatment of Primary Open-Angle Glaucoma With Cataract","Efficacy and Safety of Phacoemulsification Combined With Gonioscopy-Assisted Trabeculotomy as Initial Treatment for Primary Open-Angle Glaucoma With Cataract: A Multicenter Randomized Controlled Trial","Inclusion Criteria:\n\n* Provides written informed consent voluntarily.\n* Age 40 to 85 years.\n* Male or female.\n* Treatment-naive for glaucoma, with no prior IOP-lowering medication, glaucoma laser procedure, or glaucoma surgery.\n* Lens opacity causing decreased visual quality and clinically significant cataract.\n* Diagnosis of POAG combined with cataract by the treating ophthalmologist.\n* Best-corrected visual acuity of 0.1 or better on the Snellen chart, corresponding to LogMAR 1.0 or less.\n* Ability and willingness to complete scheduled follow-up visits and study examinations.\n\nExclusion Criteria:\n\n* Secondary glaucoma, including uveitic, pseudoexfoliative, pigmentary, steroid-induced, neovascular, traumatic, or other secondary glaucoma.\n* Angle-closure glaucoma or narrow angle inconsistent with POAG.\n* POAG without visually significant cataract.\n* Previous anti-glaucoma medication use, glaucoma surgery, or glaucoma laser treatment.\n* Advanced visual field loss, defined as visual field mean deviation worse than -12 dB.\n* Severe ocular comorbidity or inability to perform reliable visual acuity testing.\n* Known contraindication to required study medications.\n* Average RNFL thickness or GCIPL thickness less than 54 micrometers.\n* Axial length greater than 26 mm.\n* Monocular status or functional vision in only one eye.\n* Inability to complete reliable visual field or OCT testing.\n* Systemic disease that may affect ocular status or study assessment, including diabetes mellitus, uncontrolled hypertension, malignancy, renal disease, autoimmune disease, neurological disease, liver disease, cardiovascular disease, or systemic inflammatory disease.\n* Visual impairment mainly attributable to disease other than POAG or cataract.\n* Pregnancy, lactation, or planned pregnancy during the study period.",{"count":245,"type":21},[60],"The goal of this clinical trial is to learn whether doing phacoemulsification combined with gonioscopy-assisted trabeculotomy as an initial treatment can reduce the burden of glaucoma eye drops in adults with primary open-angle glaucoma and cataract. It will also learn whether this early surgical strategy improves ocular surface health and vision-related quality of life. The main questions it aims to answer are:\n\nDoes early combined surgery reduce the need for long-term glaucoma medications? Does early combined surgery improve ocular surface health compared with cataract surgery followed by guideline-based glaucoma eye drops? Does early combined surgery improve vision-related quality of life and anxiety compared with the medication-based treatment strategy? What medical problems or complications do participants have after treatment? Researchers will compare phacoemulsification combined with gonioscopy-assisted trabeculotomy to phacoemulsification followed by guideline-based topical eye pressure-lowering medications.\n\nParticipants will:\n\nUndergo cataract surgery with or without gonioscopy-assisted trabeculotomy Attend follow-up visits for 24 months after treatment Have eye pressure, visual acuity, OCT, AS-OCT, visual field, ocular surface, and safety examinations at scheduled visits Complete quality-of-life and anxiety questionnaires at scheduled visits Provide tear samples at selected visits for biomarker testing where applicable",[345],"Primary Open Angle Glaucoma and Cataracts",{"date":347,"type":39},"2026-07-14",{"date":349,"type":21},"2026-07-15",{"date":351,"type":21},"2030-12-31",{"name":45,"class":46},{"id":354,"slug":355,"hasResults":12,"nctId":356,"briefTitle":357,"officialTitle":358,"acronym":4,"eligibilityCriteria":359,"healthyVolunteers":201,"sex":17,"minAge":18,"maxAge":105,"enrollmentInfo":360,"targetDuration":4,"studyType":58,"phases":362,"briefSummary":364,"conditions":365,"keywords":369,"overallStatus":65,"whyStopped":4,"lastUpdateSubmitDate":377,"lastUpdatePostDateStruct":378,"startDateStruct":380,"completionDateStruct":381,"leadSponsor":383,"locationsCount":4},"100646267","phase-2-sancai-fengsui-decoction-for-rtom-a-multicenter-rct-100646267","NCT07692997","Sancai Fengsui Decoction for RTOM: A Multicenter RCT","A Multicenter Randomized Controlled Trial to Evaluate the Rehabilitative Efficacy of Sancai Fengsui Decoction on Radiation-Induced Oral Mucositis.","Inclusion Criteria:\n\n* Meets the diagnostic criteria for RTOM, with severity classified according to the RTOG grading system;\n* Voluntarily participates in this study and signs the informed consent form;\n* Age between 18 and 65 years;\n* Histopathologically diagnosed with non-metastatic head and neck malignancy;\n* Has received radiotherapy or concurrent chemoradiotherapy;\n* ECOG performance status score: 0-2;\n* Adequate major organ function.\n* Exclusion Criteria:\n* Patients with severe heart, lung, liver, kidney, digestive system, hematopoietic system, or nervous system diseases; acute infectious diseases; autoimmune diseases; HIV; diabetes mellitus with poor blood glucose control; or any other serious condition that, in the investigator's judgment, may increase the risk of the study, interfere with study execution or result analysis, or make the subject unsuitable for enrollment for other reasons;\n* Pregnant or breastfeeding women;\n* Allergic constitution;\n* Patients with severe psychiatric disorders, or a history of alcohol or drug abuse;\n* Participation in another clinical trial within the past 3 months;\n* Subjects deemed unsuitable for participation in this clinical study by the investigator.",{"count":361,"type":21},126,[363],"PHASE2","How to promote the prognosis and outcome of RTOM, restore oral function, and improve quality of life are key issues for improving the long-term outcomes of head and neck malignant tumor radiotherapy, and are also integral parts of the patient-centered Traditional Chinese Medicine \"prevention-treatment-rehabilitation\" system for RTOM. This project aims to thoroughly evaluate the efficacy and safety of Chinese herbal compounds in the rehabilitation phase of RTOM, targeting the long-term rehabilitation outcomes of RTOM, and to conduct a phase II clinical trial. In this project, Sancai Fengsui Decoction will be used as an oral medication to improve the rehabilitation status of RTOM, and will be compared with a placebo group. The efficacy of the oral medication will be evaluated by comparing outcome measures including the 2-week pain relief rate in the oral cavity\u002Foropharynx, the RTOG grade remission rate for RTOM, and the relief rate of xerostomia. As an important extension of TCM prevention and treatment for RTOM, this project can provide a high-level evidence-based TCM protocol for the long-term rehabilitation of RTOM.",[366,367,368],"Radiation-Induced Oral Mucositis (RTOM)","Head and Neck Cancer","Oral Mucositis of RTOG Grade Greater Than 1",[370,371,372,373,374,375,376],"Head and neck tumors","Radiation-induced oropharyngeal mucositis","Traditional Chinese Medicine (TCM) rehabilitation","phase II","double-blind","two-arm (1:1)","clinical trial","2026-07-03",{"date":379,"type":39},"2026-07-09",{"date":330,"type":21},{"date":382,"type":21},"2028-07-31",{"name":45,"class":46},{"id":385,"slug":386,"hasResults":12,"nctId":387,"briefTitle":388,"officialTitle":389,"acronym":4,"eligibilityCriteria":390,"healthyVolunteers":12,"sex":17,"minAge":391,"maxAge":18,"enrollmentInfo":392,"targetDuration":4,"studyType":58,"phases":394,"briefSummary":395,"conditions":396,"keywords":4,"overallStatus":65,"whyStopped":4,"lastUpdateSubmitDate":398,"lastUpdatePostDateStruct":399,"startDateStruct":401,"completionDateStruct":403,"leadSponsor":405,"locationsCount":4},"100644839","rituximab-combining-with-low-dose-mycophenolate-mofetil-on-proliferative-lupus-nephritis-in-children-100644839","NCT07675291","Rituximab Combining With Low-Dose Mycophenolate Mofetil on Proliferative Lupus Nephritis in Children","Efficacy and Safety of Rituximab Combining With Low-Dose Mycophenolate Mofetil in the Induction Therapy of Proliferative Lupus Nephritis in Children","Inclusion Criteria:\n\n1. Children aged 3-18 years old, regardless of sex;\n2. SLE patients who meet the 2019 EULAR\u002FACR SLE criteria or the 2012 SLICC diagnostic criteria;\n3. Diagnosed as lupus nephritis and the classification was consistent with proliferative lupus nephritis (type III or IV, with or without type V);\n4. White blood cell count ≥3.0×10\\^9\u002FL, and lymphocyte count ≥ 0.5× 10\\^9\u002FL and CD20 (or CD19)≥1\u002Ful;\n5. No cyclophosphamide or rituximab induction therapy was used before enrollment;\n6. Informed consent form is signed by the guardian and children over 8 years old;\n7. In the active stage of the disease, the 24-hour urine protein quantification ≥25mg\u002Fkg, or the urine protein\u002Fcreatinine ≥1.0mg\u002Fmg;\n8. Estimated GFR≥60ml\u002Fmin\u002F1.73m\\^2 (improved Swchartz formula).\n\nExclusion Criteria:\n\n1. Patients with lupus encephalopathy;\n2. Estimated GFR\\\u003C60ml\u002Fmin\u002F1.73m\\^2(Swchartz formula);\n3. HBV-antigen positive, HCV or HIV antibody positive;\n4. Severe infection (including chronic hepatitis, EB virus or cytomegalovirus infection) and tuberculosis;\n5. Allergic to the active ingredients or any auxiliary materials in rituximab, mycophenolate mofetil or cyclophosphamide;\n6. Severe heart failure and liver function damage;\n7. Patients who is not suitable to participate in this study judged by the researchers.","3 Years",{"count":393,"type":21},112,[60],"The objective of this study is to assess the efficacy and safety of rituximab combining with low-dose mycophenolate mofetil in the induction therapy of proliferative lupus nephritis in children.",[397],"Lupus Nephritis","2026-06-29",{"date":400,"type":39},"2026-06-30",{"date":402,"type":21},"2026-06",{"date":404,"type":21},"2028-12-31",{"name":45,"class":46},{"id":407,"slug":408,"hasResults":12,"nctId":409,"briefTitle":410,"officialTitle":411,"acronym":4,"eligibilityCriteria":412,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":413,"targetDuration":4,"studyType":58,"phases":415,"briefSummary":416,"conditions":417,"keywords":419,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":425,"lastUpdatePostDateStruct":426,"startDateStruct":428,"completionDateStruct":430,"leadSponsor":432,"locationsCount":97},"100517465","doxepin-solution-for-alleviation-of-stubborn-breakthrough-pain-induced-by-swallowing-in-patients-receiving-radiotherapy-for-nasopharyngeal-carcinoma-100517465","NCT06017895","Doxepin Solution for Alleviation of Stubborn Breakthrough Pain Induced by Swallowing in Patients Receiving Radiotherapy for Nasopharyngeal Carcinoma","Doxepin Solution for Alleviation of Stubborn Breakthrough Pain Induced by Swallowing in Patient Receiving Radiotherapy for Nasopharyngeal Carcinoma: A Multicenter, Randomized, Controlled, Double-Blind Clinical Trial","Inclusion Criteria:\n\n1. Provide informed written consent.\n2. Age ≥ 18 years.\n3. Histologically confirmed as nasopharyngeal carcinoma, and currently undergoing radical radiotherapy or chemoradiotherapy.\n4. Physical examination demonstrating the presence of radiation-induced mucositis in the oral cavity and\u002For oropharynx.\n5. At least 4 (out of 10) patient-reported swallowing-induced pain as measured by the numeric rating scale of pain.\n6. Being able to complete the questionnaires independently or with assistance.\n7. ECOG Performance Status 0, 1 or 2.\n\nExclusion Criteria:\n\n1. Known allergy to doxepin, tricyclic antidepressants, or any known component of the drug formulation.\n2. Use of a tricyclic antidepressant or monoamine oxidase inhibitor within 14 days prior to registration.\n3. Current untreated or unhealed oral candidiasis or oral herpes simplex virus infection.\n4. Untreated narrow angle glaucoma within 6 weeks prior to registration.\n5. Untreated urinary retention within 6 weeks prior to registration.\n6. Administration of cryotherapy to prevent oral mucositis within 6 weeks prior to registration.\n7. Current serious heart disease or a recent history of myocardial infarction.\n8. Current untreated or unresolved conditions like epilepsy, hyperthyroidism, hepatic dysfunction, delirium, and neutropenia.\n9. Pregnant or lactating women.",{"count":414,"type":21},178,[60],"The goal of this clinical trial is to explore the effectiveness and adverse reactions of doxepin solution spray for alleviation of stubborn breakthrough pain induced by swallowing in patients receiving radiotherapy for nasopharyngeal carcinoma.",[418],"Swallowing-induced Pain",[420,421,422,423,424],"Nasopharyngeal carcinoma","Oral mucositis","Radiotherapy","Swallowing-induced pain","Doxepin","2026-06-22",{"date":427,"type":39},"2026-06-23",{"date":429,"type":39},"2023-10-31",{"date":431,"type":21},"2026-08-31",{"name":45,"class":46},{"id":434,"slug":435,"hasResults":12,"nctId":436,"briefTitle":437,"officialTitle":438,"acronym":4,"eligibilityCriteria":439,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":440,"targetDuration":4,"studyType":58,"phases":442,"briefSummary":443,"conditions":444,"keywords":448,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":190,"lastUpdatePostDateStruct":453,"startDateStruct":455,"completionDateStruct":457,"leadSponsor":459,"locationsCount":97},"100643728","phase-2-egfr-tkis-plus-pd-1-in-egfr-mutant-advanced-nsclc-100643728","NCT07637448","EGFR-TKIs Plus PD-1 in EGFR-Mutant Advanced NSCLC","A Clinical Study Evaluating the Preliminary Antitumor Activity and Safety of EGFR-TKIs Combined With PD-1 Monoclonal Antibody as First-Line Therapy in Patients With EGFR-Mutant Advanced Non-Small Cell Lung Cancer","Inclusion Criteria:\n\n1. Patients with histologically or cytologically confirmed, previously untreated EGFR-mutant (19del\u002FL858R) locally advanced or metastatic (stage IIIB\u002FIIIC or IV) non-small cell lung cancer (NSCLC), according to the 9th edition of the TNM staging system for lung cancer jointly issued by the International Association for the Study of Lung Cancer (IASLC) and the American Joint Committee on Cancer (AJCC);\n2. Male or female patients aged ≥ 18 years;\n3. Patients who are willing to receive third-generation EGFR-TKI targeted therapy, followed by maintenance therapy with a PD-1 antibody during the stable phase of the disease (defined as no further tumor shrinkage for at least two consecutive assessments based on RECIST v1.1 criteria);\n4. Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1;\n5. At least one measurable or non-measurable but evaluable lesion according to RECIST version 1.1;\n6. Adequate organ function;\n7. Female or male patients of childbearing potential must agree to use highly effective contraceptive measures throughout the study period;\n8. Willing and able to comply with scheduled visits, treatment plans, laboratory tests, and other study requirements as specified in the visit schedule.\n\nExclusion Criteria:\n\n1. Patients who are ineligible for standard anti-tumor therapy according to routine clinical practice;\n2. Prior treatment with anti-PD-1\u002FPD-L1 immunotherapy;\n3. Concurrent enrollment in another clinical study;\n4. Known history of allogeneic organ transplantation or allogeneic hematopoietic stem cell transplantation;\n5. Receipt of systemic corticosteroids or other immunosuppressive therapy within 2 weeks prior to the first dose of study drug;\n6. Receipt of any live vaccine within 4 weeks prior to the first dose of study drug, or planned receipt of live vaccine during the study period;\n7. Presence of brainstem, leptomeningeal, spinal cord metastasis, or spinal cord compression;\n8. Presence of uncontrolled concomitant diseases, including but not limited to decompensated cirrhosis, nephrotic syndrome, uncontrolled metabolic disorders, etc.;\n9. History of severe gastrointestinal ulcer, gastrointestinal perforation, fistula or obstruction, intra-abdominal abscess, or acute gastrointestinal bleeding within 6 months prior to the first dose, or other gastrointestinal diseases that, in the investigator's opinion, may predispose to bleeding or perforation;\n10. Presence of severe uncontrolled cardiovascular disease;\n11. Interstitial lung disease (ILD) (including pulmonary fibrosis or radiation pneumonitis) requiring corticosteroid therapy, or current ILD\u002Fnon-infectious pneumonitis;\n12. Concomitant pulmonary disease resulting in clinically severe impairment of respiratory function;\n13. Chronic autoimmune disease or inflammatory disease requiring systemic therapy or receiving systemic therapy within 2 years prior to the first dose;\n14. Active or history of documented inflammatory bowel disease (e.g., Crohn's disease, ulcerative colitis, or chronic diarrhea), intestinal obstruction, or extensive bowel resection;\n15. Diagnosis of Gilbert's syndrome;\n16. Severe infection within 4 weeks prior to the first dose, including but not limited to complications requiring hospitalization, sepsis, or severe pneumonia;\n17. Known active pulmonary tuberculosis;\n18. Known active syphilis infection;\n19. Known history of immunodeficiency, or positive test for human immunodeficiency virus (HIV) antibody;\n20. Presence of active hepatitis B virus (HBV) or hepatitis C virus (HCV) infection;\n21. Known allergy to any component of any study drug, history of severe allergic reactions (e.g., anaphylactic shock), history of severe hypersensitivity to other monoclonal antibodies or recombinant protein-based substances, or history of severe infusion reactions;\n22. Women who are pregnant, breastfeeding, or planning to become pregnant or breastfeed during the study period;\n23. Any disease, medical condition, organ system dysfunction, or social circumstance (including but not limited to psychiatric illness, substance\u002Falcohol abuse, history of drug abuse, etc.) that, in the investigator's opinion, may interfere with the subject's ability to provide informed consent, adversely affect the subject's cooperation and participation in the study, or confound the interpretation of study results.",{"count":441,"type":21},32,[363],"This study is an open-label, multicenter, single-arm clinical study.",[445,446,447],"Lung Cancer Non-Small Cell Cancer (NSCLC)","EGFR Activating Mutation","PD-1 Antibody",[449,450,451,452],"Non-Small Cell Cancer (NSCLC)","EGFR-Mutant","EGFR-TKIs","PD-1 Monoclonal Antibody",{"date":454,"type":39},"2026-06-09",{"date":456,"type":39},"2026-05-21",{"date":458,"type":21},"2030-03-01",{"name":45,"class":46},{"id":461,"slug":462,"hasResults":12,"nctId":463,"briefTitle":464,"officialTitle":465,"acronym":4,"eligibilityCriteria":466,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":105,"enrollmentInfo":467,"targetDuration":4,"studyType":58,"phases":469,"briefSummary":471,"conditions":472,"keywords":4,"overallStatus":65,"whyStopped":4,"lastUpdateSubmitDate":190,"lastUpdatePostDateStruct":476,"startDateStruct":477,"completionDateStruct":479,"leadSponsor":480,"locationsCount":97},"100643343","phase-2-luspatercept-vs-epoetin-in-treating-poor-erythroid-engraftment-for-hematological-malignancies-100643343","NCT07636486","Luspatercept vs Epoetin in Treating Poor Erythroid Engraftment for Hematological Malignancies","Luspatercept Versus Epoetin in Treating Poor Erythroid Engraftment for Hematological Malignancies","Inclusion Criteria:\n\n* 18-65 years\n* Hematologic malignancies\n* Poor erythroid engraftment after the first allo-HSCT\n* Complete remission post-transplantation\n* Eastern Cooperative Oncology Group performance status of 0-2\n* Epoetin-naive\n* Endogenous serum erythropoietin concentration \\\u003C500 U\u002FL\n\nExclusion Criteria:\n\n* Life expectancy shorter than 30 days post-transplantation\n* Any abnormality in a vital sign (e.g., heart rate, respiratory rate, or blood pressure)\n* Patients with any conditions not suitable for the trial (investigators' decision)",{"count":468,"type":21},90,[363,470],"PHASE3","Allogeneic hematopoietic stem cell transplantation (allo-HSCT) is an effective therapy for hematological malignancies. Nonetheless, poor graft function remains a life-threatening complication after allo-HSCT. Poor erythroid engraftment is associated with increased bleeding events and shorter survival. Current treatment methods such as epoetin or repeated red-cell transfusions are not effective for poor erythroid engraftment, with limited and transient responses. Retrospective studies suggested that luspatercept showed efficacy in patients with anemia post-transplantation or poor erythroid engraftment. However, there are no studies comparing luspatercept versus epoetin for the treatment of poor erythroid engraftment. Therefore, we conducted a randomized controlled study to compared the effect of luspatercept versus epoetin in treating poor erythroid engraftment for hematological malignancies.",[473,474,475,110],"Luspatercept","Epoetin","Poor Erythroid Engraftment",{"date":454,"type":39},{"date":478,"type":21},"2026-06-15",{"date":351,"type":21},{"name":45,"class":46},{"id":482,"slug":483,"hasResults":12,"nctId":484,"briefTitle":485,"officialTitle":486,"acronym":487,"eligibilityCriteria":488,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":489,"enrollmentInfo":490,"targetDuration":4,"studyType":58,"phases":491,"briefSummary":492,"conditions":493,"keywords":495,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":499,"lastUpdatePostDateStruct":500,"startDateStruct":501,"completionDateStruct":503,"leadSponsor":505,"locationsCount":97},"100640679","efficacy-and-safety-of-anlotinib-combined-with-bemocizumab-for-neoadjuvant-therapy-of-esophageal-squamous-cell-carcinomaescc-100640679","NCT07627347","Efficacy and Safety of Anlotinib Combined With Bemocizumab for Neoadjuvant Therapy of Esophageal Squamous Cell Carcinoma(ESCC)","Clinical Trial on the Efficacy and Safety of Anlotinib Combined With Bemocizumab for Neoadjuvant Therapy of Resectable Esophageal Squamous Cell Carcinoma","RAOS","Inclusion Criteria:\n\n1. Aged 18-70, both male and female\n2. After gastroscopy\u002Fultrasonic gastroscopy biopsy, the pathology suggests squamous cell carcinoma of the esophagus, and the clinical diagnosis is cT2N1-2M0 or cT3N0-2M0, with TNM staging of II-III B\n3. Patients with non-cervical esophageal cance\n4. The patient has not previously received systemic or local treatment for esophageal cancer, and according to the RECIST 1.1 criteria, there is at least one measurable lesion for imaging evaluation of neoadjuvant therapy\n5. ECOG PS: 0-1\n6. Expected survival duration ≥ 12 months\n7. The subjects had no functional disorders of major organs, and the researchers assessed that thyroid, lung, liver, kidney, and heart functions were basically normal;\n8. Women of childbearing age must have already taken reliable contraceptive measures or undergone a pregnancy test (serum or urine) within 7 days prior to enrollment, with a negative result, and be willing to use appropriate contraception during the trial and for 8 weeks after the last administration of the trial medication. For males, they must agree to use appropriate contraception during the trial and for 8 weeks after the last administration of the trial medication, or have undergone surgical sterilization\n9. The subjects voluntarily joined this study, signed the informed consent form, exhibited good compliance, actively cooperated with the planned schedule by returning to the hospital for regular clinical follow-ups and necessary treatments, and cooperated with the regular collection of blood and tissue samples\n\nExclusion Criteria:\n\n1. Within the past 5 years, there has been or is currently a co-occurrence of other malignant tumors, except for cured cervical carcinoma in situ, non-melanoma skin cancer, and superficial bladder tumors \\[Ta (non-invasive tumor), Tis (carcinoma in situ), and T1 (tumor invades the basement membrane)\\]\n2. Patients with ulcerative esophageal squamous cell carcinoma\n3. Patients with esophageal fistula or tracheal fistula;\n4. Those who are allergic to anlotinib and bemusuban\n5. Those with a history of immune deficiency, including HIV-positive or suffering from other acquired or congenital immune deficiency diseases, or those who have undergone organ transplantation\n6. Patients with any severe and\u002For uncontrolled diseases\n7. Unresolved toxic reactions above CTC AE Grade 1 caused by any previous treatment, excluding alopecia;\n8. Individuals with multiple factors affecting oral medication administration, such as inability to swallow, chronic diarrhea, and intestinal obstruction\n9. Urine routine test indicates proteinuria ≥++ and confirmed 24-hour urine protein quantitation \\> 1.0 g\n10. Subjects who underwent major surgical procedures, incisional biopsies, or significant traumatic injuries within 28 days prior to grouping\n11. Abnormal coagulation function: INR \\> 1.5 or prothrombin time (PT) \\> ULN + 4 seconds or APTT \\> 1.5ULN), with a tendency to bleed or undergoing thrombolytic or anticoagulant therapy; patients who have experienced any bleeding or hemorrhagic events ≥ CTCAE Grade 3 within 4 weeks before grouping, have unhealed wounds, ulcers, or fractures\n12. Those who have experienced arterial or venous thromboembolic events within 6 months, such as cerebrovascular accidents (including transient ischemic attacks), deep vein thrombosis, and pulmonary embolism\n13. Pregnant or lactating women\n14. Patients with distant metastasis\n15. Patients with significant bone marrow suppression\n16. Suffering from mental illness or having a history of abuse of psychotropic drugs;\n17. Patients who have participated in other drug clinical trials within 4 weeks;\n18. Patients with concomitant diseases that, according to the researcher's judgment, pose serious risks to patient safety or affect patients' ability to complete the study\n19. Individuals with hereditary bleeding tendency, coagulation dysfunction, potential invasion of large blood vessels, and other bleeding risks, who have experienced clinically significant bleeding symptoms or have a clear tendency to bleed within the previous 3 months before enrollment, such as gastrointestinal bleeding, bleeding gastric ulcer, and baseline fecal occult blood test result of ++ or above\n20. Researchers consider those who are not suitable for inclusion","70 Years",{"count":7,"type":21},[60],"This study aims to explore the efficacy and safety of anlotinib combined with bemocizumab as neoadjuvant therapy for resectable esophageal squamous cell carcinoma, with the goal of improving the pathological complete response (pCR) rate and margin-negative resection(R0) resection rate in patients undergoing esophageal cancer surgery, as well as enhancing disease-free survival (DFS) in postoperative patients. This will provide guidance and new options for the treatment of patients with locally advanced esophageal cancer.",[494],"ESCC",[494,496,497,498],"Neoadjuvant therapy Immunotherapy","Chemotherapy-free","Anlotinib","2026-05-31",{"date":190,"type":39},{"date":502,"type":39},"2026-05-18",{"date":504,"type":21},"2028-12-30",{"name":45,"class":46},{"id":507,"slug":508,"hasResults":12,"nctId":509,"briefTitle":510,"officialTitle":510,"acronym":4,"eligibilityCriteria":511,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":512,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":514,"conditions":515,"keywords":4,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":517,"lastUpdatePostDateStruct":518,"startDateStruct":520,"completionDateStruct":522,"leadSponsor":523,"locationsCount":97},"100639720","correlation-analysis-of-gene-characteristics-of-malignant-tumors-with-prognosis-100639720","NCT07622667","Correlation Analysis of Gene Characteristics of Malignant Tumors With Prognosis","Inclusion Criteria:\n\n1. Voluntarily sign the informed consent form.\n2. Treated at Nanfang Hospital, Southern Medical University between January 2017 and December 2025.\n3. Eastern Cooperative Oncology Group (ECOG) performance status score of 0-2.\n4. Availability of surplus routinely discarded clinical tumor tissue samples (biopsy specimens or pathological sections) or blood samples for assays such as sequencing, staining, ELISA, drug sensitivity testing, and flow cytometry.\n\nExclusion Criteria:Patients deemed by the investigator to be unsuitable for participation in this study.",{"count":513,"type":21},500,"This study is a single-center observational investigation aimed at systematically exploring the key molecular features influencing the prognosis of malignant tumors by integrating multidimensional clinical information with multi-omics molecular data. The goal is to provide a critical scientific basis for constructing precise prognostic prediction models, identifying potential therapeutic targets, and optimizing clinical treatment strategies. The study plans to consecutively enroll adult patients with histologically confirmed malignant tumors who received antitumor therapy at our hospital between January 2017 and December 2025. Clinical data (including demographic characteristics, tumor pathology information, treatment histories, and survival follow-up data) will be systematically collected from electronic medical records. Additionally, tumor tissue or blood samples will be obtained from the patients for sequencing, staining, ELISA, drug sensitivity testing, and flow cytometry analysis to comprehensively characterize the genomic features, immune microenvironment, and cellular heterogeneity of the tumors.",[516],"Malignant Tumors","2026-05-28",{"date":519,"type":39},"2026-06-03",{"date":521,"type":21},"2026-05-29",{"date":43,"type":21},{"name":45,"class":46},{"id":525,"slug":526,"hasResults":12,"nctId":527,"briefTitle":528,"officialTitle":529,"acronym":4,"eligibilityCriteria":530,"healthyVolunteers":201,"sex":17,"minAge":18,"maxAge":55,"enrollmentInfo":531,"targetDuration":4,"studyType":58,"phases":533,"briefSummary":534,"conditions":535,"keywords":4,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":539,"lastUpdatePostDateStruct":540,"startDateStruct":542,"completionDateStruct":543,"leadSponsor":545,"locationsCount":97},"100637810","electrolyte-beverage-combined-with-polyethylene-glycol-for-colonoscopy-bowel-preparation-100637810","NCT07608120","Electrolyte Beverage Combined With Polyethylene Glycol for Colonoscopy Bowel Preparation","Randomized Controlled Trial of Different Ratios of Electrolyte Beverage and Water Combined With Polyethylene Glycol on Bowel Preparation Quality and Ingestion Rhythm Before Colonoscopy","Inclusion Criteria:\n\n* Adults aged 18-75 years scheduled to undergo elective colonoscopy\n* Meet the standard clinical indications for colonoscopy;\n* Able to understand and comply with the bowel preparation procedure and complete oral polyethylene glycol (PEG) intake as required;\n* Able to comply with study-related data collection and follow-up;\n* Provide written informed consent voluntarily.\n\nExclusion Criteria:\n\n* Previously diagnosed colorectal cancer, intestinal obstruction, or suspected intestinal obstruction;\n* Active gastrointestinal bleeding or a definite history of gastrointestinal bleeding within the past 4 weeks (including melena, hematochezia, or hematemesis);\n* Severe renal insufficiency, decompensated heart failure, significant electrolyte imbalance, or other conditions unsuitable for PEG bowel preparation;\n* Known allergy to polyethylene glycol or components of the electrolyte beverage used in the study;\n* Pregnant or breastfeeding women;\n* Any other condition considered by the investigators to make the participant unsuitable for the study.",{"count":532,"type":21},405,[60],"This randomized controlled trial aims to evaluate the effects of different ratios of electrolyte beverage and water combined with polyethylene glycol (PEG) on bowel preparation quality before colonoscopy. Participants undergoing elective colonoscopy will be randomly assigned to one of three bowel preparation regimens: PEG prepared with water only, PEG prepared with a low ratio of electrolyte beverage and water, or PEG prepared with a medium ratio of electrolyte beverage and water. The primary outcome is adequate bowel preparation assessed by the Boston Bowel Preparation Scale (BBPS). Secondary outcomes include bowel preparation completion rate, tolerability, adverse events, repeat colonoscopy rate, adenoma detection rate, and ingestion rhythm characteristics during bowel preparation. This study also aims to explore whether electrolyte beverage-assisted bowel preparation may improve bowel cleansing quality by influencing participants' ingestion rhythm and adherence during PEG intake.",[536,537,538],"Colonoscopy","Bowel Preparation Solutions","Colorectal Cancer Screening","2026-05-24",{"date":541,"type":39},"2026-05-27",{"date":502,"type":39},{"date":544,"type":21},"2027-05-31",{"name":45,"class":46},{"id":547,"slug":548,"hasResults":12,"nctId":549,"briefTitle":550,"officialTitle":551,"acronym":4,"eligibilityCriteria":552,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":553,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":555,"conditions":556,"keywords":557,"overallStatus":65,"whyStopped":4,"lastUpdateSubmitDate":502,"lastUpdatePostDateStruct":561,"startDateStruct":563,"completionDateStruct":564,"leadSponsor":566,"locationsCount":97},"100641088","efficacy-and-safety-of-indobufen-aspirin-cilostazol-and-clopidogrel-in-the-treatment-of-ischemic-stroke-100641088","NCT07604298","Efficacy and Safety of Indobufen, Aspirin, Cilostazol and Clopidogrel in the Treatment of Ischemic Stroke","Efficacy and Safety of Indobufen, Aspirin, Cilostazol, and Clopidogrel in the Treatment of Ischemic Stroke: a Single-center, Retrospective Study","Inclusion Criteria:\n\n1. Age ≥ 18 years;\n2. Diagnosed with acute ischemic stroke (AIS) patients according to the Chinese Guidelines for the Diagnosis and Treatment of Acute Ischemic Stroke 2018 ;\n3. Hospitalized in the Department of Neurology, Nanfang Hospital, Southern Medical University, between January 2020 and December 2025;\n4. Received one of the following as a secondary prevention regimen within 7 days after discharge: indobufen, aspirin, clopidogrel, or cilostazol, either as monotherapy or as dual therapy;\n5. Have follow-up records at 1 year after treatment initiation.\n\nExclusion Criteria:\n\n1. Already having long-term anticoagulant therapy at baseline;\n2. History of hemorrhagic stroke or active bleeding;\n3. Severe hepatic or renal dysfunction (defined as AST\u002FALT \\> 3 times the upper limit of normal, or estimated glomerular filtration rate \\\u003C 30 mL\u002Fmin\u002F1.73m²), end-stage disease, intracranial tumor, or intracranial infection.",{"count":554,"type":21},2000,"Through a single-center retrospective cohort study of acute ischemic stroke (AIS) patients receiving secondary prevention with indobufen, clopidogrel, cilostazol, or aspirin as monotherapy or dual therapy, we aim to compare the real-world effectiveness and safety of these four antiplatelet regimens. Through closely tracking the recurrence of stroke (including ischemic and hemorrhagic stroke) and bleeding events (GUSTO-defined) within one year of treatment, we evaluate the association between each antiplatelet agent and the risk of stroke recurrence, thereby providing critical evidence to guide individualized antiplatelet therapy in AIS patients.",[325],[558,559,560],"Stroke recurrence","Antiplatelet therapy","Secondary prevention",{"date":562,"type":39},"2026-05-22",{"date":254,"type":21},{"date":565,"type":21},"2027-06-01",{"name":45,"class":46},{"id":568,"slug":569,"hasResults":12,"nctId":570,"briefTitle":571,"officialTitle":572,"acronym":4,"eligibilityCriteria":573,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":55,"enrollmentInfo":574,"targetDuration":4,"studyType":58,"phases":575,"briefSummary":576,"conditions":577,"keywords":580,"overallStatus":65,"whyStopped":4,"lastUpdateSubmitDate":502,"lastUpdatePostDateStruct":587,"startDateStruct":588,"completionDateStruct":589,"leadSponsor":590,"locationsCount":97},"100639029","phase-2-adaptive-adjuvant-therapy-after-neoadjuvant-therapy-and-gastrectomy-for-gastric-or-gastroesophageal-junction-adenocarcinoma-100639029","NCT07603349","Adaptive Adjuvant Therapy After Neoadjuvant Therapy and Gastrectomy for Gastric or Gastroesophageal Junction Adenocarcinoma","Efficacy and Safety of Postoperative Adaptive Adjuvant Therapy After Neoadjuvant Therapy and Radical Gastrectomy for Gastric or Gastroesophageal Junction Adenocarcinoma: A Prospective, Multicenter, Open-Label Clinical Trial","Key Inclusion Criteria:\n\n1. Voluntarily signed written informed consent.\n2. Aged 18 to 75 years, inclusive, regardless of sex.\n3. Underwent radical gastrectomy with D2 or more extended lymphadenectomy and achieved R0 resection. Surgical approaches may include open or laparoscopic surgery.\n4. Histopathologically confirmed gastric or gastroesophageal junction adenocarcinoma.\n5. Received preoperative neoadjuvant immunotherapy combined with chemotherapy, including oxaliplatin plus fluoropyrimidine-based chemotherapy. Immunotherapy may include anti-PD-1 monoclonal antibodies, anti-PD-L1 monoclonal antibodies, PD-1\u002FCTLA-4 bispecific antibodies, and other immune checkpoint inhibitors.\n6. Eligible for one of the following predefined cohorts:\n\n   * Cohort 1: TRG grade 3 and postoperative pathological stage ypT3-4N2-3M0.\n   * Cohort 2: TRG grade 0 and postoperative pathological stage ypT0N0M0.\n7. ECOG performance status of 0 or 1.\n8. No evidence of metastasis or recurrence on postoperative imaging before enrollment.\n9. Adequate organ function, defined as hematologic, hepatic, renal, and thyroid function meeting the protocol-specified criteria based on laboratory tests performed within 14 days before randomization.\n10. Willing and able to comply with the study treatment, scheduled visits, laboratory tests, and other study procedures.\n11. Female participants of childbearing potential must have a negative pregnancy test before enrollment and agree to use effective contraception during the study and for 6 months after the last dose of study treatment. Male participants with female partners of childbearing potential must agree to use effective contraception during the study and for 6 months after the last dose of study treatment.\n\nKey Exclusion Criteria:\n\n1. Presence of liver, peritoneal, or other distant metastases.\n2. Inability to take oral medications.\n3. Unresolved postoperative complications at the time of randomization, such as postoperative infection, anastomotic leakage or wound dehiscence, gastrointestinal bleeding, pancreatic fistula, or intestinal obstruction.\n4. Uncontrolled pericardial effusion, uncontrolled pleural effusion, or clinically significant moderate or greater ascites at screening, defined as any of the following: pleural effusion or ascites with clinical symptoms and detectable by physical examination; or pleural effusion or ascites requiring drainage and\u002For intracavitary treatment during screening.\n5. Underwent any surgery requiring general anesthesia that was not related to gastric cancer within 28 days before randomization.\n6. History of or current diagnosis of another malignancy within 5 years.\n7. Active or prior autoimmune disease that may relapse or require immunosuppressive treatment within 2 weeks or during the study period; or a history of immunodeficiency, including HIV positivity or other acquired or congenital immunodeficiency disease; or a history of organ transplantation.\n8. Participation in another clinical study, or any condition that may interfere with the interpretation of the study results.\n9. Any other severe acute or chronic disease that, in the investigator's judgment, may increase the risk associated with study participation or study treatment.\n10. Active or uncontrolled infection requiring systemic antibiotic therapy within 2 weeks before randomization or at the time of randomization.\n11. Diagnosis of interstitial pneumonia, noninfectious pneumonitis, pulmonary fibrosis, or acute lung disease.\n12. Active tuberculosis within 1 year or previous anti-tuberculosis treatment.\n13. Female participants who are pregnant, breastfeeding, or planning to become pregnant during treatment or within 6 months after the end of treatment.\n14. History of psychotropic drug abuse with inability to discontinue, or presence of a psychiatric disorder.\n15. Patients considered unsuitable for participation in this study by the investigator.",{"count":532,"type":21},[363,470],"The goal of this clinical trial is to evaluate postoperative adaptive adjuvant therapy in patients with gastric or gastroesophageal junction adenocarcinoma after neoadjuvant chemotherapy plus immunotherapy and radical gastrectomy.The main questions it aims to answer are:\n\n1. In patients with poor pathological response, does switching to a alternative postoperative treatment regimen improve survival?\n2. In patients with complete pathological response, can observation without routine postoperative treatment maintain favorable survival outcomes? Participants will be assigned to different cohorts according to their pathological response after surgery and will be followed regularly for recurrence, survival, and treatment-related side effects.",[578,579],"Gastric Adenocarcinoma","Gastroesophageal Junction Adenocarcinoma",[581,582,583,584,585,586],"Gastric cancer","Gastroesophageal junction cancer","Neoadjuvant therapy","Adaptive adjuvant therapy","Pathological response","Prognosis",{"date":562,"type":39},{"date":402,"type":21},{"date":135,"type":21},{"name":45,"class":46},{"id":592,"slug":593,"hasResults":12,"nctId":594,"briefTitle":595,"officialTitle":595,"acronym":596,"eligibilityCriteria":597,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":598,"targetDuration":4,"studyType":58,"phases":600,"briefSummary":602,"conditions":603,"keywords":4,"overallStatus":65,"whyStopped":4,"lastUpdateSubmitDate":502,"lastUpdatePostDateStruct":605,"startDateStruct":606,"completionDateStruct":608,"leadSponsor":609,"locationsCount":4},"100637504","phase-4-efficacy-and-safety-of-nefecon-on-prevention-of-relapse-of-iga-nephropathy-a-randomized-double-blinded-placebo-controlled-trial-100637504","NCT07604311","Efficacy and Safety of Nefecon on Prevention of Relapse of IgA Nephropathy: a Randomized, Double-blinded, Placebo-Controlled Trial","NeFRIN","Inclusion Criteria:\n\n* Diagnosed primary IgAN with biopsy verification.\n* Female or male participants ≥18 years of age.\n* Completion of 9 months of Nefecon 16 mg QD at the Baseline visit.\n* Proteinuria ≥ 1g\u002Fd prior to initiation of Nefecon\n* Proteinuria\\\u003C0.5 g\u002Fday (or UPCR \\\u003C0.5 g\u002Fg) at screening\n* eGFR ≥30 ml\u002Fmin\u002F1.73m² at screening\n* On stable treatment with supportive treatment（including RAASi, SGLT2i, ERA） for at least 1 month prior to the Baseline visit\n\nExclusion Criteria:\n\n* Systemic diseases that may cause mesangial immunoglobulin A deposition, including but not limited to IgAVN, systemic lupus erythematosus, dermatitis herpetiformis, ankylosing spondylitis, and others;\n* Presence of other glomerulopathies (e.g., C3 glomerulopathy, nephrotic syndrome and\u002For diabetes nephropathy), active infection, severe hepatic impairment (Child-Pugh Class C), congestive heart failure, and a history of malignant tumor within the past 5 years.\n* On current or planned dialysis or kidney transplantation;\n* Participants who have been treated with systemic glucocorticoids and immunosuppressive agents within the past 3 months, including mycophenolate mofetil, hydroxychloroquine, cyclophosphamide, azathioprine, leflunomide, calcineurin inhibitors, and Chinese traditional medicines with immunosuppressive effects (such as Tripterygium wilfordii, Sinomenium acutum, Tripterygium Glycosides Tablets, Kunxian Capsules, Kunming Shanhaitang Tablets, etc.); treatment with B-cell targeted biological agents (such as telitacicept, etc.); complement pathway inhibitors, etc.;\n* Poorly controlled diabetes mellitus (HbA1c\\>8%）\n* Poorly controlled hypertension （≥160\u002F100mmHg）\n* Participants taking potent inhibitors of cytochrome P450 (CYP) 3A4.\n* Females who are pregnant, breastfeeding, or plan to become pregnant in the trial period.\n* Any other conditions that, in the investigator's judgment, make the patient ineligible for this clinical study.",{"count":599,"type":21},288,[601],"PHASE4","IgA nephropathy (IgAN) is a chronic progressive kidney disease, and long-term control of proteinuria and prevention of relapse are crucial for delaying disease progression. Patients with IgAN who achieve proteinuria remission after receiving Nefecon for 9 months or longer still face the risk of proteinuria relapse after treatment discontinuation. This study is to evaluate the efficacy and safety of Nefecon 8 mg treatment for 15 months as a maintenance therapy for prevention of proteinuria relapse in proteinuria-remitted patients.",[604],"IgA Nephropathy (IgAN)",{"date":562,"type":39},{"date":607,"type":21},"2026-05-01",{"date":404,"type":21},{"name":45,"class":46},""]